In a recent development, the “Global CD3 Antibodies Market, Dosage, Price, Sales & Clinical Trials Insight 2028” report has been released by ResearchAndMarkets shedding light on the robust growth of the CD3 antibodies market, particularly in the context of cancer indications.
CD3 protein, recognized as a promising therapeutic target, has witnessed the development of several antibodies and anti-CD3 antibodies over the years, contributing to the market entry of effective treatments. Although the CD3 antibodies market predominantly caters to cancer indications, its dynamic nature presents undiscovered potential, making it an area worth exploring.
The report outlines the history of CD3-directed drugs, emphasizing the pivotal role played by Muromonab-CD3 and Removab (Catumaxomab), the pioneering CD3 antibodies. Notably, despite their withdrawal from the market for various reasons, they paved the way for subsequent antibodies that have achieved regulatory approval from the FDA and EMA.
Among the approved antibodies, Blincyto (CD19 CD3) stands out, having entered the market in 2015 and demonstrating significant commercial success in treating acute lymphoblastic leukemia. The report highlights Blincyto’s impressive revenue of US$ 583 million in 2022, with continued strong performance in the first half of 2023.
It is worth noting that the remaining eight CD3 antibodies received approval between 2022 and 2023, albeit limited to specific regions under accelerated approval programs. The report anticipates potential competition to Blincyto’s market dominance as developers seek approvals in additional regions.
The clinical development landscape of CD3 antibodies primarily revolves around cancer indications such as multiple myeloma, lymphoma, uveal melanoma, and leukemia. Most CD3 antibody candidates in development adopt the bispecific antibody approach, specifically T cell engagers. Companies like Lindis Biotech, BioAtla, AstraZeneca, Regeneron, and Amgen are actively involved in developing CD3 bispecific T cell engagers.
The global CD3 antibodies market is poised for substantial growth, driven by factors such as increasing market value, ongoing clinical trials, and the involvement of major pharmaceutical corporations. The report emphasizes the market’s untapped potential, with proprietary platforms enabling the development of unique CD3 antibodies for rare indications, supported by regulatory benefits like orphan drug designation.
Key Highlights from the Report:
1. Global CD3 Antibodies Market Opportunity: Expected to surpass USD 5 billion by 2028.
2. Global & Regional Market Trends Analysis: Offers insights into current market trends, developments, and clinical trials.
3. CD3 Antibodies Clinical Trials Insight: Provides a comprehensive overview of 250 CD3 antibodies in clinical trials.
4. Approved CD3 Antibodies: Details dosage, patent, pricing, and sales insights on commercially approved CD3 antibodies.
5. Competitive Landscape: Profiles key players in the CD3 antibodies market, including Abpro Therapeutics, Amgen, Genentech, Pfizer, Regeneron Pharmaceuticals, Roche, and others.
In conclusion, the global CD3 antibodies market presents a promising landscape with substantial growth potential, driven by ongoing clinical development and the commercial success of approved antibodies.